BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

BTIG analyst Marie Thibault has maintained a Buy rating on Haemonetics (NYSE: HAE) and increased the price target from $110 to $130. This adjustment reflects a positive outlook on the company's performance.